Diabetes Mellitus Clinical Trial
— PALSOfficial title:
Family Diabetes Study (Family PALS (PArtners in Lifestyle Support)
NOTE: This study is in the trial-phase of a 5-year study that included a formative research
phase (Phase 1 - IRB study # 07-1765 "Family-based Diabetes Self-management Training for
African American Adults"). During the first phase, eight focus groups were conducted with 68
participants and a validation study with 215 African American patients with type 2 diabetes.
The data gathered in Phase 1 informs the refinement of the intervention in this phase.
Purpose: The overall goal of this research is to evaluate, in a randomized controlled trial,
a family-based diabetes self-management intervention for overweight/obese African American
adults with type 2 diabetes (the "index participants") and a paired overweight family member
(co-participant) who does not have diabetes. The primary outcome is weight change in the
index participant.
| Status | Completed |
| Enrollment | 108 |
| Est. completion date | September 2012 |
| Est. primary completion date | September 2012 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 21 Years to 75 Years |
| Eligibility |
Person with diabetes. Inclusion Criteria: - self-described African American 21-75 years of age; - self-reported diagnosis of type 2 diabetes; - A1c value = 11%; - currently under the care of a physician or other health care provider; - able to participate in moderate level physical activity; - willing to lose 5% or more of initial body weight and follow recommendations for healthy dietary and physical activity patterns; - access to a phone and willing to complete a telephone-administered survey; - English speaking. Exclusion Criteria: - any medical contraindication to weight loss; - cardiovascular event within the past 6 months; - evidence of active cancer diagnosis; - pregnant or lactating; - self-reported history of renal disease other than kidney stones; - any history of gastric bypass surgery or scheduled surgery for this purpose; - weight loss of >20 lbs in the last 3 months; - current use of medications for weight loss, treatment of psychosis or manic-depressive illness. Family Members: Inclusion criteria (NOTE: 'Family' for this study is defined as 'a group of intimates living together or in close proximity with strong emotional bonds (identification, attachment, loyalty, reciprocity, solidarity), and with strong, ongoing personal ties. Family members can only participate if paired with an African American study participant.): - 21 -75 years of age; - living with or married (for at least 1 year) to an African American adult diagnosed with diabetes; - self-described as a blood relative of an African American with diabetes with whom there is regular, ongoing contact; - overweight/obesity defined as a BMI between 25 to 47, inclusive; - English-speaking; - able to participate in moderate level physical activity; - willing to lose 5% or more of initial body weight and follow recommendations for healthy dietary and physical activity patterns; - access to a phone and willing to complete a telephone-administered survey. Exclusion Criteria: - self-reported diagnosis of type 2 diabetes (the A1c test used in this study cannot be used for diagnostic purposes; additionally, the initial therapy of most newly diagnosed patients with type 2 diabetes includes lifestyle changes and weight loss); - any medical contraindication to weight loss; - cardiovascular event within the past 6 months; - evidence of active cancer diagnosis; - pregnant or lactating; - self-reported history of renal disease other than kidney stones; - any history of gastric bypass surgery or scheduled surgery for this purpose; - weight loss of > 20 lbs in the last 3 months; - current use of medications for weight loss, treatment of psychosis or manic-depressive illness. Family members do not themselves have to be self-described African Americans. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| United States | UNC Center for Health Promotion and Disease Prevention (HPDP) | Chapel Hill | North Carolina |
| Lead Sponsor | Collaborator |
|---|---|
| University of North Carolina, Chapel Hill | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in body weight | Change in weight from start to end of the 20-weekly group-based intervention. NOTE: Weekly sessions are not held during weeks where holidays occur on a scheduled session date (such that the duration of the intervention may be more than 20 weeks). | 6 months | No |
| Secondary | Effect on Hemoglobin A1c | A1c change from enrollment to post-intervention. | 6 months (post-intervention) | No |
| Secondary | Lifestyle behaviors | Diet and physical activity behavior changes (from enrollment or baseline to post-intervention) | 6 months | No |
| Secondary | Blood pressure change | Change in systolic and diastolic blood pressure from baseline (enrollment) to post-intervention | 6 months | No |
| Secondary | Change in psychosocial factors | Changes in measures of family functioning, social support and social relationships, self-efficacy, perceived barriers to diabetes self-care, and quality of life; comparing baseline to post-intervention. | 6 months | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |